产品
编 号：F743969
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1312797-14-0
产品详情
生物活性：
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition.
体内研究：
Parsatuzumab (anti-EGFL7) enhances the antiangiogenesis, tumor growth control, and survival associated with antiVEGF monotherapy in several xenograft and genetically engineered murine tumor models.Parsatuzumab (50 mg/kg; i.v.; 3 times per week) targets EGFL7 and inhibits mantle cell lymphoma (MCL) cell growth and prolongs survival in mouse models of MCL.Animal Model:NSG mice injected with Rec1 cells (s.c.)
Dosage:50 mg/kg
Administration:Intravenous injection; 3 times per week; sacrificed mice when tumor reached end point criteria
Result:Significantly decreased tumor volume than IgG and increased survival of mice.
体外研究：
EGFL7 is a vascular-restricted extracellular matrix protein that promotes endothelial cell adhesion and survival.Parsatuzumab (48 h) inhibits cell proliferation and increases apoptosis against patient-derived xenograft (PDX) cells.
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition.
体内研究：
Parsatuzumab (anti-EGFL7) enhances the antiangiogenesis, tumor growth control, and survival associated with antiVEGF monotherapy in several xenograft and genetically engineered murine tumor models.Parsatuzumab (50 mg/kg; i.v.; 3 times per week) targets EGFL7 and inhibits mantle cell lymphoma (MCL) cell growth and prolongs survival in mouse models of MCL.Animal Model:NSG mice injected with Rec1 cells (s.c.)
Dosage:50 mg/kg
Administration:Intravenous injection; 3 times per week; sacrificed mice when tumor reached end point criteria
Result:Significantly decreased tumor volume than IgG and increased survival of mice.
体外研究：
EGFL7 is a vascular-restricted extracellular matrix protein that promotes endothelial cell adhesion and survival.Parsatuzumab (48 h) inhibits cell proliferation and increases apoptosis against patient-derived xenograft (PDX) cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备